Scientific Letter Bilimsel Mektup 589The anthelmintic drug, diethylcarbamazine citrate (DECC), is a piperazine derivative (1). DECC has been used in the treatment of filarial infections. It has been demonstrated that intravenous DECC administration into anaesthetized cats induces hypotension, bradycardia and a reduction in +dP/dt max (the maximum rate of increase in the left ventricular pressure) followed by hypertension and an increase in +dP/dt max and the myocardial blood flow (2). It is possible that DECC affects cardiovascular functions, but little is known about its mechanisms of action during these cardiac effects. In isolated rat hearts, the possible action of DECC on the left ventricular developed pressure (LVDP), +dP/dt max , the heart rate, the coronary flow, -dP/dt min (the maximum rate of decrease in the left ventricular pressure) and the left ventricular end-diastolic pressure (LVEDP) has not been investigated, and the signal transduction pathways mediating the actions of DECC are not known. Therefore, we studied the possible cardiovascular effects of DECC in isolated rat hearts. We postulated that the activation of sarcoplasmic reticulum Ca 2+ ATPase inhibitor (SERCA) and the muscarinic receptors, as well as nitric oxide (NO) generation, may be responsible for the cardiac effects of DECC, and we also studied whether SERCA, muscarinic receptors or NO mediate the effects of DECC.All procedures were approved by the local research ethics committee. Male and female Sprague-Dawley rats weighing 300-400 g were used. One hour after the administration of 1000 IU heparin ip., the heart was rapidly excised under the administration of light ether anesthesia. The aorta was immediately attached to a stainless steel cannula of the perfusion system and the hearts were perfused under a constant pressure. The perfusion solution was Modified Krebs-Henseleit solution and this solution was continuously oxygenated with 95% O 2 and 5% CO 2 (pH=7.4). The temperature was maintained at 37°C.A liquid-filled latex balloon was connected to a pressure transducer (Isotec, Hugo Sachs Electronic, March-Hugstetten, Germany) and inserted into the left ventricle via the mitral valve. The peak systolic pressure and LVEDP were measured. LVDP (an index of cardiac contractility) was calculated as the difference between the systolic and the diastolic pressures, and this pressure was accepted as the contractile force. Furthermore, +dP/dt max (other index of contractility), heart rate and -dP/dt min (an index of relaxation) were determined from the left ventricular pressure signal using the data acquisition software. The coronary flow, which is an index of the coronary vascular tone, was measured from the timed collection of the coronary effluent in a graduated cylinder. The hearts were allowed to equilibrate for 30 minutes to establish a stable baseline. After the stabilization period, DECC (20, 100 and 500 µM) was infused to the hearts for 30 minutes using an infusion pump (Graseby Medical, Model 3400, Watford Herts, England). Ten nM tha...